Fig. 5
From: CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
a Concentration-time profile (mean ± SD) of CS1003 after a single dose was administered to naive cynomolgus monkeys (3 males + 3 females per dose group). b The percentages of occupied PD-1 receptors on total T cells (b) and CD8+ cells (c) were determined by flow cytometry.
